EXTENDED REPORT

Consensus-based recommendations for the management of juvenile dermatomyositis

Felicitas Bellutti Enders, 1,2 Brigitte Bader-Meunier, 3 Eileen Baildam, 4 Tamas Constantin, 5 Pavla Dolezalova, 6 Brian M Feldman, 7 Pekka Lahdenne, 8 Bo Magnusson, 9 Kiran Nistala, 10 Seza Ozen, 11 Clarissa Pilkington, 10 Angelo Ravelli, 12 Ricardo Russo, 13 Yosef Uziel, 14 Marco van Brussel, 15 Janjaap van der Net, 15 Sebastiaan Vastert, 1 Lucy R Wedderburn, 10 Nicolaas Wulffraat, 1 Liza J McCann, 4 Annet van Royen-Kerkhof 1

ABSTRACT

Background In 2012, a European initiative called Single Hub and Access point for pediatric Rheumatology in Europe (SHARE) was launched to optimise and disseminate diagnostic and management regimens in Europe for children and young adults with rheumatic diseases. Juvenile dermatomyositis (JDM) is a rare disease within the group of paediatric rheumatic diseases (PRDs) and can lead to significant morbidity. Evidence-based guidelines are sparse and management is mostly based on physicians’ experience. Consequently, treatment regimens differ throughout Europe.

Objectives To provide recommendations for diagnosis and treatment of JDM.

Methods Recommendations were developed by an evidence-informed consensus process using the European League Against Rheumatism standard operating procedures. A committee was constituted, consisting of 19 experienced paediatric rheumatologists and 2 experts in paediatric exercise physiology and physical therapy, mainly from Europe. Recommendations derived from a validated systematic literature review were evaluated by an online survey and subsequently discussed at two consensus meetings using nominal group technique. Recommendations were accepted if >80% agreement was reached.

Results In total, 7 overarching principles, 33 recommendations on diagnosis and 19 recommendations on therapy were accepted with >80% agreement among experts. Topics covered include assessment of skin, muscle and major organ involvement and suggested treatment pathways.

Conclusions The SHARE initiative aims to identify best practices for treatment of patients suffering from PRD. Within this remit, recommendations for the diagnosis and treatment of JDM have been formulated by an evidence-informed consensus process to produce a standard of care for patients with JDM throughout Europe.

INTRODUCTION

In 2012, Single Hub and Access point for pediatric Rheumatology in Europe (SHARE) was launched with the aim of optimising and disseminating diagnostic and management regimens for children and young people with rheumatic diseases. This includes juvenile dermatomyositis (JDM); the focus of this paper. Clear recommendations can help clinicians in the care of patients with JDM as no international consensus regarding diagnosis and treatment is currently available and management therefore varies.

METHODS

A committee of 19 experts in paediatric rheumatology, 2 experts in exercise physiology and physical therapy was established to develop recommendations for JDM based on consensus, but evidence informed, using the European League Against Rheumatism (EULAR) standard operating procedures for developing best practice. 1 2

Systematic literature search

The electronic databases PubMed/MEDLINE, Embase and Cochrane were searched twice for eligible articles in June 2013 and subsequently in February 2015. All synonyms of JDM were searched in MeSH/Emtree terms, title and abstract. Reference tracking was performed in all included studies (full search strategy in online supplementary figure S1). Experts (FBE, LJMC, AvR-K) selected papers relevant to JDM investigations and/or treatment to be taken forward for validity assessment (inclusion and exclusion criteria shown in online supplementary figure S1). All full-text scored papers are listed in online supplementary list S1.

Validity assessment

A panel of experts (two per paper) independently assessed the methodological quality of papers meeting inclusion criteria (see online supplementary figure S1) and extracted data using predefined scoring forms for diagnostic 3 and therapeutic studies. 4 Disagreements were resolved by discussion or by the opinion of a third expert. Adapted classification tables for diagnostic 5 and therapeutic 5 epidemiological studies were used to determine the level of evidence and strength of each recommendation.

Establishment of recommendations

As part of the EULAR standard operating procedures, experts described the main results and conclusions of each paper, along with validity and level of evidence. These descriptions were collated by three experts (FBE, LJMC and AvR-K) and used to formulate provisional recommendations (N=65).
A summary of the evidence was presented along with each provisional recommendation to the expert committee (n=21) in an online survey (with 100% response rate). Recommendations were revised according to responses and discussed at two sequential face-to-face consensus meetings in March 2014 (Genova, number of experts participating: N=13) and 2015 (Barcelona, number of experts participating: N=15), using Nominal Group Technique. A non-voting expert (AR) facilitated the process. Recommendations were accepted when ≥80% of the experts agreed.

RESULTS

Literature review

The literature search yielded 3429 unique papers. After title/abstract and subsequent full-text screening, 115 articles met the inclusion criteria and were selected for quality scoring: 45 articles for therapy, 70 for diagnosis and 3 articles for both groups (detailed in online supplementary figure/list S1). An important manuscript detailing a randomised controlled trial involving treatment with prednisolone, methotrexate (MTX) and ciclosporin was published after the systematic review and consensus meetings, but before submission of this manuscript. With the results of this paper considered, the level of evidence of two recommendations in the therapy section was updated, but the phrasing was not changed.9

Recommendations

The following section describes recommendations with corresponding supporting literature. Tables 1–3 summarise the recommendations, their levels of evidence, recommendation strength and percentage of expert agreement for each. Of note, 39 out of the 59 recommendations accepted are based on expert opinion (level of evidence 4, a strength of evidence D). Recommendations not reaching ≥80% agreement are listed in online supplementary table T1 (N=6).

Overarching principles

JDM is the most common idiopathic inflammatory myopathy of childhood, but the incidence is very low; 2–4 cases per million children per year (table 1).10 Standardisation of diagnostic tests and treatment regimens will enable collaborative research studies to increase knowledge of this rare disease.11 JDM vasculopathy principally affects muscles and skin, but may affect other organs and cause constitutional symptoms. With early treatment, 30–50% of patients have the potential to reach remission within 2–3 years of disease onset with few complications and a mortality rate of <4%.12–15 However, polyclyclic or persistently active disease has been described in 41–60% of cases in recent cohort studies (depending on activity measures used) and complications like calcinosis, persistent muscle weakness, skin or muscle atrophy remain problematic.12 14–19 Risk of lipodystrophy and calcinosis has been associated with greater duration of active disease and inadequate corticosteroid therapy.15 17 20 21 Quality of life may be impaired compared with healthy controls13 in both physical and psychosocial domains, requiring psychosocial support. In view of the rarity and seriousness of the condition, it was agreed that children with JDM should be cared for in centres with experience and expertise in this condition. Treatment goals include control of disease activity, prevention of organ damage and improvement in quality of life with participation in daily activities. Evaluation of treatment response (including measurement of disease activity or disease damage and monitoring adverse effects of immunosuppressive medication) is an important cornerstone of management.22–24 Many standardised tools, developed primarily for research, are available for this, including the disease activity score (DAS) and myositis disease activity assessment tool.25 It is recognised that registries provide useful resources to investigate rare disease such as JDM.11 In order to better understand prognosis and enhance therapeutic development of this rare disease,

Table 1 Overarching principles for juvenile dermatomyositis (JDM)

<table>
<thead>
<tr>
<th>Principle</th>
<th>L</th>
<th>S</th>
<th>Agreement (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All children with suspected idiopathic inflammatory myopathies should be referred to a specialised centre.</td>
<td>4</td>
<td>D</td>
<td>100</td>
</tr>
<tr>
<td>High-risk patients need immediate/urgent referral to a specialised centre. High risk patients are defined by</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. Severe disability, defined by inability to get off bed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B. CMAS score &lt;15, or MMT8 score &lt;30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. Presence of aspiration or dysphagia (to the point of inability to swallow)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D. Gastrointestinal vasculitis (as determined by imaging or presence of bloody stools)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E. Myocarditis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F. Parenchymal lung disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G. Central nervous system disease (defined as decreased level of consciousness or seizures)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H. Skin ulceration</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I. Requirement for intensive care unit management</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>J. Age &lt;1 year</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For JDM, patient-/parent-reported outcome measures are helpful when assessing disease activity and should be used at diagnosis and during disease monitoring.</td>
<td>4</td>
<td>D</td>
<td>100</td>
</tr>
<tr>
<td>Validated tools should be used to measure health status, for example, the Childhood Health Assessment Questionnaire, patient/parent visual analogue scale, Childhood Health Questionnaire, Juvenile Dermatomyositis Multi-dimensional Assessment Report.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All children with JDM should have disease activity (muscle, skin, major organ) assessed regularly in a standardised way, using tools such as the Disease Activity Score.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All children with JDM should have disease damage assessed at least yearly using a standardised disease damage measure, such as the Myositis Damage Index.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All patients with JDM should have the opportunity to be registered within a research registry/repository, for example, the Euromyositis registry.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Agreement indicates percentage of experts that agreed on the recommendation during the final voting round of the consensus meeting. 1A, meta-analysis of randomised controlled trial; 1B, randomised controlled study; 2A, controlled study without randomisation; 2B, quasi-experimental study; 3, descriptive study; 4, expert opinion; A, based on level 1 evidence; B, based on level 2 or extrapolated from level 1; C, based on level 3 or extrapolated from level 1 or 2; CMAS, Childhood Myositis Assessment Scale; D, based on level 4 or extrapolated from level 3 or 4 expert opinion; L, level of evidence; MMT, Manual Muscle Test; S, strength of recommendation;
Table 2  Recommendations regarding diagnosis

(a) General recommendations
In the absence of cutaneous signs and/or failure to respond as expected to therapy, alternative diagnoses should be considered including metabolic or mitochondrial myopathies and dystrophies.  
4 D 100
In every patient in whom a diagnosis of JDM is considered, the following list of investigations should be considered:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th>Agreement (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Muscle enzymes—including creatinine phosphokinase (CPK), LDH, AST (SGOT), ALT (SGPT), adolase (if available)</td>
<td>4 D</td>
<td>94</td>
</tr>
<tr>
<td>B. Full blood count and blood film</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. ESR (or plasma viscosity) and CRP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D. Myositis-specific and myositis-associated antibodies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>E. Renal function and liver function tests</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F. Infection screen (for differential diagnosis)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>G. Investigations for alternative systemic causes of myopathy including endocrine disorders (especially thyroid function), electrolyte disturbances, vitamin D deficiency</td>
<td></td>
<td></td>
</tr>
<tr>
<td>H. Further tests for metabolic/mitochondrial myopathies (especially in the absence of rash/atypical presentation)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I. Urine dipstick (with further evaluation if positive for protein)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>J. Nailfold capillaroscopy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>K. Echocardiogram and ECG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>L. Pulmonary function tests (chest X-ray and HRCT if concern)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M. MRI of muscles (+quantitative ultrasound)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N. EMG (particularly if suspicion of neuropathy/disorder of neuromuscular junction)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>O. Muscle biopsy (especially in the absence of rash/atypical presentation)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P. MRI brain if neurological involvement suspected</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Q. Abdominal ultrasound scan</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(b) Specific recommendations
Assessment of muscle involvement
Both muscle strength and function should be tested at diagnosis and follow up by formal validated measures, such as the MMT8 and the CMAS.  
2a-3 B–C 100
MRI can be used to aid diagnosis of JDM.  
2B B 100
MRI can be used to help monitor disease activity.  
2B B 100
When used, MRI should be carried out by defined protocols that enhance detection of muscle inflammation, such as T2 weighted/STIR sequences.  
3 C 100
MRI should be interpreted by an expert radiologist.  
4 D 100
A muscle biopsy should be done in all cases where the presentation of JDM is atypical; in particular in the absence of rash/skin signs.  
4 D 100
If a muscle biopsy is performed for diagnosis of JDM, a standardised JDM biopsy score tool should be used to quantify severity of histological abnormalities.  
2B B 100
Expert histopathological opinion is required to define features of inflammation in JDM muscle biopsy.  
4 D 100
When doing a muscle biopsy, there is insufficient evidence to recommend a needle biopsy as opposed to an open biopsy in children.  
3 C 100
In cases where MRI or muscle biopsy is not possible, increased muscle echo intensity on muscle ultrasonography (when performed by an experienced sonographer) may be indicative of myositis.  
2B C 82
Swallow function should be formally assessed in every patient. The assessment may include a speech and language therapy assessment, video fluoroscopy/barium studies.  
3 C 100
EMG or nerve conduction velocity should be considered to differentiate myopathy from neuropathy when diagnosis of JDM is uncertain.  
4 D 100
EMG does not detect metabolic myopathies reliably and further workup is required if this diagnosis is suspected.  
3 D 100
Assessment of skin involvement
Assessment of nailfold capillaries should be used to aid diagnosis of JDM.  
2 B 100
At time of diagnosis or disease flare, standardised nailfold capillaroscopy assessment is recommended. During follow-up, assessment of nailfold capillaroscopy should be performed regularly.  
3 C 100
A formal CAT should be used to aid diagnosis of JDM.  
4 D 100
A formal CAT should be used to monitor skin disease activity over time.  
2B B 100
Skin tools may include the DAS (skin), MITAX (skin) or CAT.  
4 D 100
Assessment of lung involvement
All patients with JDM should have an assessment of lung involvement at time of diagnosis.  
3 C 100
Assessment should include pulmonary function tests, including CO diffusion. If pulmonary function tests are indicative of interstitial lung disease, further investigations (CXR/ HRCT) are needed.  
4 D 100
Assessment of cardiac involvement.
All patients with JDM should have echocardiography and ECG at diagnosis.  
4 D 94
Patients at particular risk of cardiac dysfunction should have repeated cardiac evaluation. Risk factors include hypertension, high disease activity 1 year post diagnosis, long-term high corticosteroid burden or chronic ongoing active disease.  
2B B 100
Assessment of calcinosis
Calciosis should be looked for in all patients with JDM.  
4 D 94
Plain radiographs may be used for the evaluation of calcinosis.  
3 C 100

Continued
Table 2 Continued

<table>
<thead>
<tr>
<th>Autoantibodies and biomarkers</th>
<th>L</th>
<th>S</th>
<th>Agreement (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>We recommend use of muscle enzymes (CPK, LDH, AST) for diagnosis and disease monitoring in JDM, although it must be recognised muscle enzymes may be normal despite active disease.</td>
<td>4</td>
<td>D</td>
<td>100</td>
</tr>
<tr>
<td>Measurement of von Willebrand factor does not provide any additional information for diagnosis of JDM.</td>
<td>3</td>
<td>C</td>
<td>100</td>
</tr>
<tr>
<td>There is no significant diagnostic benefit gained from measurement of antinuclear antibody in JDM.</td>
<td>4</td>
<td>D</td>
<td>100</td>
</tr>
<tr>
<td>Measurement of myositis-specific autoantibodies (such as anti-TIF-1-γ (p155), anti-NXP2/p140/MJ), anti-MDA5 and anti-SRP) should be considered, when available.</td>
<td>2A-3</td>
<td>B-C</td>
<td>100</td>
</tr>
<tr>
<td>In patients with overlap features, measurement of myositis-associated-antibodies such as anti-PmScI, anti-U1-RNP, anti-La (‘SSB’), anti-Ro (‘SSA’) and anti-Sm may be helpful to clarify the diagnosis.</td>
<td>4</td>
<td>D</td>
<td>100</td>
</tr>
<tr>
<td>Further validation studies are recommended to define the use of more sensitive biomarkers in JDM.</td>
<td>4</td>
<td>D</td>
<td>100</td>
</tr>
</tbody>
</table>

Agreement indicates percentage of experts that agreed on the recommendation during the final voting round of the consensus meeting.

1A, meta-analysis of randomised controlled trial; 1B, randomised controlled study; 2A, controlled study without randomisation; 2B, quasi-experimental study; 3, descriptive study; 4 expert opinion; A, based on level 1 evidence; B, based on level 2 or extrapolated from level 1; ALT, alanine aminotransferase; AST, aspartate aminotransferase; C, based on level 3 or extrapolated from level 1 or 2; CAT, Cutaneous Assessment Tool; CMAS, Childhood Myositis Assessment Scale; CO, carbon monoxide; CRP, C-reactive protein; CXR, chest X-ray; D, based on level 4 or extrapolated from level 3 or 4 expert opinion; EMG, electromyogram; ESR, erythrocyte sedimentation rate; HRCT, high-resolution computed tomography; L, level of evidence; LDH, lactate dehydrogenase; MITAX, myositis intention to treat activity index; MMT, Manual Muscle Test; RNP, anti-ribonuclear protein; S, strength of recommendation; SGDT, Serum Glutamic-Oxaloacetic Transaminase; SGPT, Serum Glutamic-Pyruvic Transaminase; SRP, signal recognition particle; SSA, Ro antibodies; SSB, Sjögren’s syndrome type B antibodies; STIR, Short-T1 Inversion Recovery.

Table 3 Recommendations regarding treatment

<table>
<thead>
<tr>
<th>Sun protection, including the routine use of sunblock on sun-exposed areas should be encouraged for patients with JDM.</th>
<th>L</th>
<th>S</th>
<th>Agreement (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>When treating patients with JDM, it is particularly important to have a physiotherapist and a specialist nurse actively involved as part of a multidisciplinary team.</td>
<td>4</td>
<td>D</td>
<td>100</td>
</tr>
<tr>
<td>Treatment of JDM should include a safe and appropriate exercise programme, monitored by a physiotherapist.</td>
<td>4</td>
<td>D</td>
<td>100</td>
</tr>
<tr>
<td>We recommend the induction regimen for treatment of new onset patients with JDM to be based on high dose of corticosteroids (oral or intravenous) combined with MTX.</td>
<td>1B</td>
<td>A</td>
<td>100</td>
</tr>
<tr>
<td>High-dose corticosteroids should be administered systemically either orally or intravenously in moderate–severe JDM.</td>
<td>2A</td>
<td>B</td>
<td>100</td>
</tr>
<tr>
<td>High-dose corticosteroids should be administered intravenously if there are concerns about absorption.</td>
<td>3</td>
<td>C</td>
<td>100</td>
</tr>
<tr>
<td>Corticosteroid dose should be weaned as the patient shows clinical improvement.</td>
<td>4</td>
<td>D</td>
<td>100</td>
</tr>
<tr>
<td>Addition of MTX or ciclosporin A leads to better disease control than prednisolone alone; safety profiles favour the combination of methotrexate and prednisolone.</td>
<td>1B</td>
<td>A</td>
<td>100</td>
</tr>
<tr>
<td>MTX should be started at a dose of 15–20 mg/m²/week (max absolute dose of 40 mg/week) preferably administered subcutaneously at disease onset.</td>
<td>4</td>
<td>D</td>
<td>100</td>
</tr>
<tr>
<td>If a newly diagnosed patient has inadequate response to treatment, intensification of treatment should be considered within the first 12 weeks, after consultation with an expert centre.</td>
<td>4</td>
<td>D</td>
<td>100</td>
</tr>
<tr>
<td>Intravenous immunoglobulin may be a useful adjunct for resistant disease, particularly when skin features are prominent.</td>
<td>2B-4</td>
<td>C</td>
<td>100</td>
</tr>
<tr>
<td>MMF may be a useful therapy for muscle and skin disease (including calcinosis).</td>
<td>3</td>
<td>C</td>
<td>100</td>
</tr>
<tr>
<td>Ongoing skin disease reflects ongoing systemic disease and therefore should be treated by increasing systemic immunosuppression. Topical tacrolimus (0.1%)/topical steroids may help localised skin disease, particularly for symptomatic redness or itching.</td>
<td>4</td>
<td>D</td>
<td>100</td>
</tr>
<tr>
<td>In patients who are intolerant to methotrexate, change to another DMARD, including ciclosporin A or MMF.</td>
<td>3</td>
<td>C</td>
<td>100</td>
</tr>
<tr>
<td>For patients with severe disease (such as major organ involvement/extensive ulcerative skin disease), addition of intravenous cyclophosphamide should be considered.</td>
<td>3</td>
<td>C</td>
<td>100</td>
</tr>
<tr>
<td>B cell depletion therapy (rituximab) can be considered as an adjunctive therapy for those with refractory disease. Clinicians should be aware that rituximab can take up to 26 weeks to work.</td>
<td>1B</td>
<td>D</td>
<td>100</td>
</tr>
<tr>
<td>Anti-TNF therapies can be considered in refractory disease; infliximab or adalimumab are favoured over etanercept.</td>
<td>3</td>
<td>D</td>
<td>92</td>
</tr>
<tr>
<td>In the presence of developing or established calcinosis, intensification of immunosuppressive therapy should be considered.</td>
<td>3</td>
<td>C</td>
<td>100</td>
</tr>
<tr>
<td>There is no high-level evidence of when to stop therapy; however, consideration may be given to withdrawing treatment if a patient has been off steroids and in remission on methotrexate (or alternative DMARD) for a minimum of 1 year.</td>
<td>4</td>
<td>D</td>
<td>100</td>
</tr>
</tbody>
</table>

Agreement indicates percentage of experts that agreed on the recommendation during the final voting round of the consensus meeting.

1A, meta-analysis of randomised controlled trial; 1B, randomised controlled study; 2A, controlled study without randomisation; 2B, quasi-experimental study; 3, descriptive study; 4 expert opinion; A, based on level 1 evidence; B, based on level 2 or extrapolated from level 1; C, based on level 3 or extrapolated from level 1 or 2; D, based on level 4 or extrapolated from level 3 or 4 expert opinion; DMARD, disease-modifying antirheumatic drug; JDM, juvenile dermatomyositis; L, level of evidence; MMF, mycophenolate mofetil; MTX, methotrexate; S, strength of recommendation; STIR, Short-T1 Inversion Recovery.

the expert group found it important to recommend that all patients JDM should have the opportunity to participate in a research registry.

Recommendations regarding diagnosis

Diagnostic criteria for dermatomyositis, established by Bohan and Peter in 1975, include five items: characteristic skin rash,
proximal muscle weakness, raised muscle enzymes, myopathic changes on electromyogram (EMG) and typical muscle biopsy (table 2). These are currently being revised through the International Myositis Classification Criteria Project. Current practice reveals the necessity of broadening diagnostic criteria by incorporating new techniques, such as MRI and ultrasound, and the significance of skin disease in JDM. The expert group suggested a non-exhaustive list of investigations for consideration in every patient in whom the diagnosis of JDM is suspected. More specific recommendations have also been established.

**Assessment of muscle disease**

Muscle strength should be formally tested using validated measures of muscle testing such as the Childhood Myositis Assessment Scale (CMAS) and Manual Muscle Test (MMT). Both tools have been validated as reliable and useful tests to assess muscle strength at diagnosis and follow-up. They are important outcome measurements in clinical trials and form part of the Paediatric Rheumatology International Trials Organization (PRINTO) remission criteria. Some of the CMAS manoeuvres are age dependent. It has been shown that healthy children up to 9 years do not always achieve the maximum CMAS score of 52, hence, definition of active disease/remission should include a lower threshold in younger children. MRI is a reliable tool to assess inflammation in muscle at time of diagnosis and can also help to differentiate active and inactive disease during follow-up. Protocols that enhance detection of muscle inflammation, such as T2-weighted (fat-suppressed) imaging techniques, should be used. An expert radiologist should evaluate MRI findings.

Surveys and recent cohort studies demonstrate increasing use of MRI over time (26–89.9%) as a diagnostic modality in contrast to decreasing use of muscle biopsy (36–65%) and EMG (7.6–55.5%)[14 15 21 28 29 40] The expert group recommend EMG or nerve conduction velocity only when diagnosis is uncertain. Of note, EMG does not reliably detect metabolic myopathies.

The expert group advises biopsy when presentation is atypical or diagnosis is in doubt. Use of a standardised JDM biopsy score tool to quantify severity of histological abnormalities is recommended. Different markers have been suggested to typify muscle inflammation in patients with JDM, like major histocompatibility complex (MHC) class I, vascular cell adhesion molecule (VCAM), intercellular adhesion molecule (ICAM), CD59 and toll-like receptor (TLR), but these need further validation. Expert histopathological opinion is required to define use of these markers for diagnosis of JDM based on muscle biopsy findings. The literature suggests that needle biopsy is a safe and cost-effective alternative to open biopsy in adult patients. However, this has not been evaluated sufficiently in children to result in a recommendation.

Ultrasonography has been found in small patients cohorts (7–10 patients) to be a useful tool for myositis. The expert group suggests that when MRI or muscle biopsy is not possible muscle ultrasonography may be an alternative to assess myositis activity.

The literature suggests that swallowing dysfunction, including silent aspiration, is under-recognised and not always predicted by generalised muscle weakness. The expert group recommend that patients at risk of swallowing difficulties (eg, those presenting with nasal speech or coughing during swallowing) should have an objective assessment based on local experience (speech and language therapy assessment, video fluoroscopy/barium studies).

**Assessment of skin disease**

The expert group recommend use of a cutaneous assessment tool (CAT), including nailfold capillaroscopy to detect perinuclear capillary changes, as part of assessment of JDM skin activity at diagnosis and follow-up. This can be done in clinic with the aid of magnification using an otoscope, ophthalmoscope or dermatoroscope, or defined by formal capillaroscopy. Evidence suggests that nailfold capillary density is a sensitive measure of skin and muscle disease activity. The importance of residual skin changes in JDM is increasingly recognised, with persistent capillary abnormalities and Gottron’s papules at 6 months being associated with longer time to remission. The expert group therefore recommend that follow-up of patients with JDM should include use of a CAT. Different tools are available, including the Das (skin), Myositis Intention to Treat Activity IndeX (MITAX, skin), CAT, Dermatomyositis Skin Severity Index or Cutaneous Dermatomyositis Disease Area and Severity Index; the last two less frequently used in children. There is currently insufficient evidence that any one tool is superior to the other.

**Assessment of JDM-associated lung disease**

Lung involvement (interstitial lung disease (ILD)) is present in only ~8% of patients, and often asymptomatic, but assessment is important since ILD is a significant cause of morbidity and mortality. The expert group determined that all children should have assessment of lung involvement at time of diagnosis by pulmonary function tests, including carbon monoxide (CO) diffusion capacity. Further testing is necessary in those with an abnormal restrictive pattern, preferably in collaboration with a paediatric pulmonologist. The performance of pulmonary function tests can be difficult in very young children and can also be affected by general muscle weakness. High-resolution CT is a non-invasive and sensitive test for detecting ILD in JDM, but radiation risk associated with repeated CT scan must be considered. There is insufficient evidence to advise on frequency of assessment during follow-up, but physicians should be aware of the long-term risk of lung involvement especially in those with a high myositis damage index (MDI) score and a regular assessment of lung function may be prudent in patients that have positive anti-RNA synthetase antibodies.

**Assessment of JDM-associated cardiac disease**

Understanding of cardiac manifestations in JDM is limited. One long-term complication is hypertension due to steroid treatment. Case studies report the presence of pericarditis, endocarditis and cardiac arrhythmias. Recent evidence using echocardiography has detected systolic and diastolic dysfunction, particularly in patients with high long-term organ damage scores (MDI, follow-up) and high early skin (but not muscle) disease activity (Das skin, year 1). Notably, most patients were asymptomatic. The authors of the study suggest that vasculopathy in the myocardium resembles vasculopathy in the skin.

The long-term clinical consequences of abnormal echocardiographic findings in asymptomatic patients with JDM are unclear. The expert group recommends cardiac evaluation by ECG and echocardiography for all patients. Repeated cardiac evaluation should be considered in patients with high risk of cardiac involvement; risk factors include hypertension, high disease activity 1 year post diagnosis, long-term high corticosteroid burden or chronic ongoing active disease. Echocardiographic changes are recognised even when patients are in clinical remission and thus long-term cardiac evaluation should be considered for patients at high risk. There is currently insufficient evidence to advise on frequency and duration of monitoring.
Assessment of calcinosis
Calcinosi is a well-recognised complication in patients with JDM, often occurring later in disease course, on average 2.9 years after disease onset. The expert group recommends actively looking for calcinosis by manual palpation, with the use of plain radiographs where needed. CT has been found to have no additional benefit over radiographs for detecting calcinosis.

Biomarkers and autoantibodies
Muscle enzymes are not always elevated at diagnosis of JDM and are poorly responsive to changing disease activity. Consensus processes have demonstrated differences in opinion regarding inclusion of muscle enzymes as a core set measure of activity. The International Myositis Association and Clinical Studies Group (IMACS) core set includes muscle enzymes, but the PRINTO core set excludes muscle enzymes due to their poor statistical performance. Despite these limitations, muscle enzymes are easily accessible and practice surveys suggest that the enzymes are used in routine care at diagnosis and during follow-up. The expert group recommends measurement of all listed enzymes at diagnosis (table 2) and follow-up as one of them may be elevated in the presence of a normal creatine phosphokinase (CPK). From current literature, there is no evidence that the von Willebrand factor provides additional information compared with muscle enzymes. Several markers of immunological activation appear to correlate with disease activity or potentially with worse disease outcome in JDM, but further studies are needed to determine their sensitivity, like interferon (IFN)-I chemokine signatures and neopterin. Antinuclear antibodies are frequently positive in patients with JDM (prevalence varies through different populations), but no diagnostic value has been established. Increasing evidence supports association between serotype and clinical phenotype. Myositis-specific autoantibodies target either nuclear or cytoplasmic components involved in gene transcription, protein translocation and antiviral responses. The literature suggests that the presence of anti-p155 (anti-TIF1γ) myositis-associated antibodies (MAA) predicts worse cutaneous involvement, anti-p140 (also known as NXP-2 or MJ), predicts calcinosis, severe disease course and persistent disease activity, and anti-MDA5 is associated with increased risk of skin and oral ulceration, arthritis, milder muscle disease and interstitial lung disease. The association with severe lung disease was most striking in Japanese patients. Anti-signal recognition particle (SRP) is associated with necrotising autoimmune myopathy. The studies mentioned above provide control numbers of patients with JDM, but also by limited tools or biomarkers to measure outcome. Currently, there is no uniform, simple and practical tool to evaluate improvement or inactive disease to guide individual treatment. PRINTO and IMACS have developed preliminary definitions of improvement (DoI) for use in clinical trials, which include multiple assessments of core set measures (CSMs). Although the CSMs used within DoIS differ slightly, PRINTO and IMACS both expect at least 20% improvement in three out of six CSMs with no more than one or two other core set measures getting worse and muscle strength not allowed to worsen. These definitions and recommendations are best suited to clinical trials, with appropriate infrastructure, but are time consuming in clinical practice. In 2012, CARRA developed a single-consensus steroid taper plan, including when and how to stop steroids. However, the SHARE expert group did not agree to a specific steroid-tapering regimen.

Therapy
Early and aggressive therapy may prevent or stabilise organ damage and disease complications like calcinosis, the latter being associated with significant morbidity due to pain and risk of infection (table 3). JDM treatment is largely based on experience of the treating paediatric rheumatologist. Management is complex and warrants a multidisciplinary approach including physiotherapists, specialist nurses and paediatric rheumatologists, with other specialists, as needed, for example, cardiologist/pulmonologist. The mainstay of therapy is high-dose corticosteroid initially in combination with disease-modifying drugs like MTX or cyclosporin A (CsA). Evidence for treatment is limited and often confined to small case-controlled studies, with the exception of two randomised controlled trials. In 2010, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) reached consensus on treatment plans for moderately severe JDM for the first two months after diagnosis that include a combination of steroid (intravenous methylprednisolone followed by oral prednisolone or high-dose oral prednisolone alone) and MTX or intravenous immunoglobulin (IVIG). The only randomised controlled trial for newly diagnosed patients was performed by PRINTO from 2006 to 2011, comparing three commonly used protocols (prednisone alone vs combination of prednisone with either MTX or CsA). The combination of steroids and MTX had the best outcome for efficacy and safety. In 2013, a randomised controlled trial was published for use of rituximab in refractory myositis, including JDM, in a delayed start design. There was no statistically significant difference between treatment groups, but 83% of patients met the definition of improvement by trial completion. These data, with the ability to taper glucocorticoid therapy and good re-treatment response, suggest that rituximab may be useful in refractory cases of myositis.

The expert group proposed recommendations for treatment of newly diagnosed patients and resistant disease. Treatment of refractory patients with or without calcinosis is still a challenge. Treatments used for refractory disease include IVIG, cyclophosphamide, CsA, azathioprine, mycophenolate mofetil (MMF), hydroxychloroquine, tacrolimus, infliximab and autologous stem cell transplantation. No head-to-head or superiority trial has been carried out. Published data suggest that early aggressive treatment may decrease incidence of calcinosis. Increasing evidence supports association between serotype and clinical phenotype. Myositis-specific autoantibodies target either nuclear or cytoplasmic components involved in gene transcription, protein translocation and antiviral responses. The literature suggests that the presence of anti-p155 (anti-TIF1γ) myositis-associated antibodies (MAA) predicts worse cutaneous involvement, anti-p140 (also known as NXP-2 or MJ), predicts calcinosis, severe disease course and persistent disease activity, and anti-MDA5 is associated with increased risk of skin and oral ulceration, arthritis, milder muscle disease and interstitial lung disease. The association with severe lung disease was most striking in Japanese patients. Anti-signal recognition particle (SRP) is associated with necrotising autoimmune myopathy. The studies mentioned above provide control numbers of patients with JDM, but also by limited tools or biomarkers to measure outcome. Currently, there is no uniform, simple and practical tool to evaluate improvement or inactive disease to guide individual treatment. PRINTO and IMACS have developed preliminary definitions of improvement (DoI) for use in clinical trials, which include multiple assessments of core set measures (CSMs). Although the CSMs used within DoIS differ slightly, PRINTO and IMACS both expect at least 20% improvement in three out of six CSMs with no more than one or two other core set measures getting worse and muscle strength not allowed to worsen. These definitions and recommendations are best suited to clinical trials, with appropriate infrastructure, but are time consuming in clinical practice. In 2012, CARRA developed a single-consensus steroid taper plan, including when and how to stop steroids. However, the SHARE expert group did not agree to a specific steroid-tapering regimen.

In 2012, PRINTO published criteria defining clinically inactive disease; necessitating fulfilment of three out of four variables from CPK ≤150 U/L, CMAS ≥48, MMT8 ≥78 and...
PGA score of overall disease activity $\leq 0.2$. These criteria are weighted towards muscle disease, and when tested in a Norwegian cohort, CPK was found not to differentiate well between active and inactive disease. When tested in a UK cohort, without PGA, there was a high incidence of skin disease, leading to the suggestion that PGA should be an essential criterion since it is the only measure that includes skin activity. The expert group determined that treatment should be escalated if a patient has inadequate response to treatment, including isolated skin disease.

**Figure 1A** Flow chart for the treatment of mild/moderate disease in newly diagnosed and refractory patients with juvenile dermatomyositis (JDM).

*such as major organ involvement / extensive ulcerative skin disease

** improvement based on clinician opinion

MTX – Methotrexate, MMF – Mycophenolate Mofetil, IVIG – intravenous immunoglobulins
There is no high-level evidence regarding when to stop immunosuppressive therapy. The expert group suggested considering the withdrawal of MTX (or alternative disease-modifying drug) once the patient is in remission and off steroids for a minimum of 1 year.

Based on consensus recommendations, a flow chart was established for JDM treatment (figure 1).

DISCUSSION
The JDM working group of SHARE formulated a total of 62 recommendations for the diagnosis and management of JDM, based on a systematic literature review and consensus procedure. In total, 7 overarching principles, 33 recommendations on diagnosis and 19 on therapy were accepted with >80% agreement among the experts. Topics include assessment of skin, muscle...
and major organ involvement and treatment suggestions at disease onset and in refractory disease.

Diagnostic criteria in JDM are under revision, but will need further adjustment as new outcome tools, especially autoantibodies and biomarkers, are being developed.

Close monitoring of patients’ disease status and well-being by an experienced multidisciplinary team is essential for a good clinical outcome. Recent evidence highlights the importance of treating skin disease aggressively as it is associated with high morbidity. Long-term follow-up studies are warranted to clarify complication risks. Given the disease rarity, international collaboration is crucial to recruit sufficient patients. Validated scores for disease activity and damage are needed in order to perform a structured assessment of outcome. Disease activity and damage scores have been developed, principally for clinical trials, but may be challenging and time consuming to use in daily clinical practice.

To conclude, this SHARE initiative is based on expert opinion informed by the best available evidence and provides recommendations for the diagnosis and treatment of patients with JDM, along with other paediatric rheumatic diseases129 with a view to improving the outcome for patients with JDM in Europe. It will now be important to broaden discussion and test acceptability of these to the wider community.

Author affiliations
1Department of Pediatric Immunology, Wilhelmina Children’s Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands
2Division of Allergology, Immunology and Rheumatology, Department of Pediatrics, University Hospital, Lausanne, Switzerland
3Department for Immunology, Hematology and Pediatric Rheumatology, Necker Hospital, APHP, Institut IMAGINE, Paris, France
4Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
52nd Department of Pediatrics, Semmelweis Hospital, Budapest, Hungary
6Paediatric Rheumatology Unit, Department of Paediatrics and Adolescent Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
7Division of Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
8Department of Pediatric Rheumatology, Children’s Hospital, Helsinki University Central Hospital, Helsinki, Finland
9Paediatric Rheumatology Unit, Astrid Lindgren Children’s Hospital, Karolinska University Hospital Stockholm, Sweden
10Centre for Adolescent Rheumatology, Institute of Child Health University College London, London, UK
11Department of Paediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey
12Università degli Studi di Genova and Istituto Giannina Gaslini, Genoa, Italy
13Service of Immunology and Rheumatology, Hospital de Pediatría Garrahan, Buenos Aires, Argentina
14Department of Paediatrics, Meir Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
15Division of Pediatrics, Child Development and Exercise Center, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands

Twitter Follow Ricardo Russo at @el_reumatologo

Acknowledgements This SHARE initiative has been endorsed by the executive committee of the Paediatric Rheumatology European Society and the International Society of Systemic Auto-Inflammatory Diseases.

Contributors LJM and Arv-K are senior authors. NW and SV designed the SHARE initiative. FBE performed the systematic literature review, supervised by LJM and ARK. Validity assessment of selected papers was done by FBE, BB-M, BMF, CP, AR, MvB, JvdN, SV, LRM, NW, LJM and Arv-K. Recommendations were formulated by FBE, LJM and Arv-K. The expert committee consisted of FBE, BB-M, EB, TC, PD, BMF, PL, BM, KN, CP, SO, Arv-K, RR, YU, JvdN, NW, LRM, MvB, SV, LJM and Arv-K; they completed the online surveys and/or participated in the subsequent consensus meetings, AR assisted in the preparation of the two live consensus meetings with FBE, LJM, Arv-K and facilitated the consensus procedure using nominal group technique. FBE, Arv-K and LJM wrote the manuscript, with contribution and approval of all co-authors.

Funding This project was supported by a grant from European Agency for Health and Consumers (EAC), grant number 20111202.

Competing interests FBE—Valeria e Ettore Bossi Foundation. EB—spokesperson for Roche/ Chugai, Ad Board for Abbvie and Pfizer. BMF—consultant for Novartis, Pfizer, BMS. PL—consultant for BMS, Pfizer. SO—consultant for Novartis, speaker bureau of SOBI. PD—consultant for Roche, speaker bureau for Pfizer, Novartis, grant support from SOBI, Novartis, Abbvie, Roche, Pfizer, Medac. AR—grant/research support from Pfizer and The Myositis Association; consultant for Novartis, Roche; speaker bureau of Abbvie, Novartis, Pfizer, Roche. YU—consultant for Novartis, speaker bureau of Abbvie, Neopharm, Novartis, Roche. NW—grant/research support from EAHC, Abbvie, GSK, Roche, consultant for Genzyme, Novartis, Pfizer, Roche

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Clinical and epidemiological research


Rider LG, Werth VP, Huber AM, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physical global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDAI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). *Arthritis Care Res (Hoboken)* 2011;63(Suppl 1):S118–57.


Ruperto N, Ravelli A, Pistorio A, et al. The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of...


